Characterization of autotransplant-related thrombocytopenia by evaluation of glycocalicin and reticulated platelets.
Thrombocytopoiesis of 21 multiple myeloma patients undergoing single or double transplant regimen was characterized by measuring the level of reticulated platelets and plasma glycocalicin. Since reticulated platelets are an index of thrombopoietic activity and glycocalicin plasma values are related to platelet damage and turnover, it may be possible to perform a novel type of analysis of the thrombopoietic compartment during the mobilizing regimen and during transplant-related chemotherapy. Patients underwent mobilizing therapy and first transplant. Some randomized patients also underwent a second transplant with mobilized peripheral blood stem cells. The results show that the percentage of reticulated platelets decreased after therapy and then gradually increased in the recovery phase either during first or second transplant. By contrast, the percentage of reticulated platelets increased until day +8 and then gradually decreased during the mobilizing regimen. The glycocalicin index (glycocalicin plasma value normalized for the individual platelet count) increased significantly both during the course of mobilization and after transplant-related chemotherapy when the platelet number was at its nadir. However, the glycocalicin index was more elevated after transplant-related chemotherapy than after the mobilizing regimen. Our findings suggest that chemotherapy-related thrombocytopenia may be due to a dual mechanism: thrombocytopenia results from decreased platelet production in addition to increased platelet damage and possible destruction.
Catani
L
L
Hematology and Medical Oncology Institute LA Seràgnoli, University of Bologna, Italy.
Vianelli
N
N
Luatti
S
S
Rizzi
S
S
Castellani
S
S
Valdrè
L
L
Lemoli
R M
RM
Tura
S
S
D018952:Antigens, CD34 / Q000097:blood; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001521:Behavior Therapy; D015415:Biomarkers / Q000097:blood; D001792:Blood Platelets / Q000737:chemistry*; D002066:Busulfan / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D019650:Hematopoietic Stem Cell Mobilization / Q000009:adverse effects; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage; D009101:Multiple Myeloma / Q000628:therapy; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D010976:Platelet Count / Q000187:drug effects; D019038:Platelet Glycoprotein GPIb-IX Complex / Q000378:metabolism*; D012313:RNA / Q000097:blood / Q000187:drug effects; D012156:Reticulocytes / Q000187:drug effects*; D013921:Thrombocytopenia / Q000209:etiology / Q000628:therapy*; D014182:Transplantation, Autologous / Q000009:adverse effects*; D014750:Vincristine / Q000008:administration & dosage
D018952:Antigens, CD34; D015415:Biomarkers; D010975:Platelet Aggregation Inhibitors; D019038:Platelet Glycoprotein GPIb-IX Complex; C023592:glycocalicin; D016179:Granulocyte Colony-Stimulating Factor; D014750:Vincristine; D012313:RNA; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D002066:Busulfan; D008558:Melphalan